Published in Nat Rev Genet on March 13, 2017
Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. Nat Rev Cardiol (2017) 0.90
Genetics of Triglycerides and the Risk of Atherosclerosis. Curr Atheroscler Rep (2017) 0.75
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Multiplex genome engineering using CRISPR/Cas systems. Science (2013) 55.53
RNA-guided human genome engineering via Cas9. Science (2013) 48.29
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet (1994) 40.72
The ENCODE (ENCyclopedia Of DNA Elements) Project. Science (2004) 38.24
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet (2008) 25.83
Genomewide association analysis of coronary artery disease. N Engl J Med (2007) 24.38
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med (2006) 23.83
Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet (2008) 20.73
A common allele on chromosome 9 associated with coronary heart disease. Science (2007) 20.37
A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science (2007) 18.96
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet (2012) 17.29
Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med (2007) 16.95
Biological insights from 108 schizophrenia-associated genetic loci. Nature (2014) 16.13
Genetic mapping in human disease. Science (2008) 15.12
Systematic localization of common disease-associated variation in regulatory DNA. Science (2012) 14.47
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov (2010) 14.09
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015) 13.90
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet (2005) 12.12
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature (2010) 12.07
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet (2003) 11.67
The Genotype-Tissue Expression (GTEx) project. Nat Genet (2013) 10.77
Genetic heterogeneity in human disease. Cell (2010) 10.67
Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2015) 10.14
Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med (2008) 9.83
Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med (2009) 8.73
Discovery and refinement of loci associated with lipid levels. Nat Genet (2013) 7.86
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med (1994) 7.47
Guidelines for investigating causality of sequence variants in human disease. Nature (2014) 7.30
Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science (2000) 6.73
The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet (2008) 6.72
Rare and common variants: twenty arguments. Nat Rev Genet (2012) 6.67
9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response. Nature (2011) 6.25
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med (2015) 6.12
A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet (2010) 6.07
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med (2015) 5.59
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47
A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet (2011) 5.23
New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet (2009) 5.12
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA (2004) 4.63
Mutation in LDL receptor: Alu-Alu recombination deletes exons encoding transmembrane and cytoplasmic domains. Science (1985) 4.51
Full coverage for preventive medications after myocardial infarction. N Engl J Med (2011) 4.51
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet (2010) 4.46
Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med (2014) 4.41
Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science (2001) 4.32
Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc Natl Acad Sci U S A (2010) 4.30
LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science (2007) 4.27
A form of the metabolic syndrome associated with mutations in DYRK1B. N Engl J Med (2014) 4.01
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet (2014) 3.94
Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease. N Engl J Med (2016) 3.88
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet (2013) 3.87
Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet (2015) 3.75
Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. N Engl J Med (2016) 3.68
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Young candidates for coronary heart disease. J Am Med Assoc (1951) 3.50
Searching for missing heritability: designing rare variant association studies. Proc Natl Acad Sci U S A (2014) 3.47
Rare-variant association analysis: study designs and statistical tests. Am J Hum Genet (2014) 3.42
Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science (2003) 3.34
Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med (2008) 3.33
Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC). Proc Natl Acad Sci U S A (2010) 3.33
Bayesian refinement of association signals for 14 loci in 3 common diseases. Nat Genet (2012) 3.31
Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature (2014) 3.29
Angptl4 protects against severe proinflammatory effects of saturated fat by inhibiting fatty acid uptake into mesenteric lymph node macrophages. Cell Metab (2010) 2.95
Validating therapeutic targets through human genetics. Nat Rev Drug Discov (2013) 2.94
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90
A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet (2015) 2.84
Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus. Arterioscler Thromb Vasc Biol (2009) 2.79
Evaluating the heritability explained by known susceptibility variants: a survey of ten complex diseases. Genet Epidemiol (2011) 2.78
Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci U S A (1989) 2.68
Association of genetic variation on chromosome 9p21 with susceptibility and progression of atherosclerosis: a population-based, prospective study. J Am Coll Cardiol (2008) 2.56
Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet (2001) 2.45
Heritability of death from coronary heart disease: a 36-year follow-up of 20 966 Swedish twins. J Intern Med (2002) 2.42
Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA (2014) 2.39
Genetic susceptibility to coronary artery disease: from promise to progress. Nat Rev Genet (2006) 2.32
Large-scale gene-centric analysis identifies novel variants for coronary artery disease. PLoS Genet (2011) 2.27
Dysfunctional nitric oxide signalling increases risk of myocardial infarction. Nature (2013) 2.24
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet (2015) 2.09
Sibling cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. JAMA (2005) 2.05
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. N Engl J Med (2015) 2.03
Lipoprotein(a) and risk of type 2 diabetes. Clin Chem (2010) 2.01
Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ (2016) 2.01
Health and population effects of rare gene knockouts in adult humans with related parents. Science (2016) 1.90
Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice. Proc Natl Acad Sci U S A (2007) 1.88
ANRIL expression is associated with atherosclerosis risk at chromosome 9p21. Arterioscler Thromb Vasc Biol (2010) 1.87
Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. J Clin Invest (2012) 1.71
Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll Cardiol (2016) 1.68
Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history. Eur Heart J (2015) 1.65
Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res (2014) 1.58
Variant ASGR1 Associated with a Reduced Risk of Coronary Artery Disease. N Engl J Med (2016) 1.51
Genomic prediction of coronary heart disease. Eur Heart J (2016) 1.49
Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels. J Am Coll Cardiol (2016) 1.46